PT1305041E - Medicamento para a imunoterapia de tumores malignos - Google Patents
Medicamento para a imunoterapia de tumores malignosInfo
- Publication number
- PT1305041E PT1305041E PT01958002T PT01958002T PT1305041E PT 1305041 E PT1305041 E PT 1305041E PT 01958002 T PT01958002 T PT 01958002T PT 01958002 T PT01958002 T PT 01958002T PT 1305041 E PT1305041 E PT 1305041E
- Authority
- PT
- Portugal
- Prior art keywords
- immunotherapy
- medication
- malignant tumors
- tumors
- medicament
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- 238000002255 vaccination Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00116362 | 2000-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1305041E true PT1305041E (pt) | 2006-09-29 |
Family
ID=8169380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT01958002T PT1305041E (pt) | 2000-07-28 | 2001-07-21 | Medicamento para a imunoterapia de tumores malignos |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20030129206A1 (pt) |
| EP (1) | EP1305041B1 (pt) |
| JP (1) | JP2004505058A (pt) |
| AT (1) | ATE330626T1 (pt) |
| AU (1) | AU2001279775A1 (pt) |
| BG (1) | BG107482A (pt) |
| CA (1) | CA2417374A1 (pt) |
| CY (1) | CY1105179T1 (pt) |
| CZ (1) | CZ299669B6 (pt) |
| DE (1) | DE50110274D1 (pt) |
| DK (1) | DK1305041T3 (pt) |
| ES (1) | ES2267800T3 (pt) |
| HK (1) | HK1055562A1 (pt) |
| HU (1) | HUP0300772A3 (pt) |
| NO (1) | NO20030420L (pt) |
| PL (1) | PL358675A1 (pt) |
| PT (1) | PT1305041E (pt) |
| SI (1) | SI1305041T1 (pt) |
| SK (1) | SK822003A3 (pt) |
| WO (1) | WO2002009745A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030211971A1 (en) * | 2001-09-17 | 2003-11-13 | Srivastava Pramod K. | Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins |
| CN1764375A (zh) * | 2003-02-20 | 2006-04-26 | 康涅狄格大学健康中心 | 使用包括热休克蛋白或α－2－巨球蛋白的组合物治疗癌症和传染病的方法 |
| US7674456B2 (en) * | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
| MY160857A (en) * | 2006-02-03 | 2017-03-31 | Malaysian Palm Oil Board | A cancer vaccine |
| EP1974742A1 (en) * | 2007-03-29 | 2008-10-01 | LipoNova AG | A method for improving the manufacturing process of a tumour vaccine |
| CN102470167A (zh) | 2009-07-02 | 2012-05-23 | Ith免疫治疗控股公司 | 基于外泌体的癌症治疗 |
| CN105807053B (zh) | 2016-04-15 | 2019-04-02 | 苏州药明康德新药开发股份有限公司 | 一种肿瘤解离试剂在流式细胞检测中的应用 |
| ES2908885T3 (es) | 2017-07-05 | 2022-05-04 | Vcc Medical Deutschland Gmbh | Método para fabricar una vacuna tumoral |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077519A (en) * | 1993-01-29 | 2000-06-20 | University Of Pittsburgh | Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients |
| DE19633731A1 (de) * | 1996-08-21 | 1998-02-26 | Johann Hinrich Prof Dr Peters | Hybridzellen zur Steigerung der Immunogenität von Tumorzellen |
| US6602709B1 (en) * | 1998-02-20 | 2003-08-05 | The Rockefeller University | Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells |
| DE19812004A1 (de) * | 1998-03-19 | 1999-09-30 | Forschungszentrum Juelich Gmbh | Dehydrogenasen mit verbesserter NAD-Abhängigkeit, deren Herstellung und Verwendung |
| EP1064390A4 (en) * | 1998-03-20 | 2002-06-12 | Genzyme Corp | IMPROVED ANTI-TUMOR IMMUNITY |
| JP2002510642A (ja) * | 1998-04-02 | 2002-04-09 | ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | ヒト患者における抗原提示細胞および抗腫瘍応答の増強法 |
| US6045990A (en) * | 1998-07-09 | 2000-04-04 | Baust; John M. | Inclusion of apoptotic regulators in solutions for cell storage at low temperature |
-
2001
- 2001-07-21 DE DE50110274T patent/DE50110274D1/de not_active Expired - Fee Related
- 2001-07-21 SK SK82-2003A patent/SK822003A3/sk unknown
- 2001-07-21 HU HU0300772A patent/HUP0300772A3/hu unknown
- 2001-07-21 JP JP2002515298A patent/JP2004505058A/ja not_active Abandoned
- 2001-07-21 EP EP01958002A patent/EP1305041B1/de not_active Expired - Lifetime
- 2001-07-21 SI SI200130618T patent/SI1305041T1/sl unknown
- 2001-07-21 ES ES01958002T patent/ES2267800T3/es not_active Expired - Lifetime
- 2001-07-21 AT AT01958002T patent/ATE330626T1/de not_active IP Right Cessation
- 2001-07-21 DK DK01958002T patent/DK1305041T3/da active
- 2001-07-21 PL PL01358675A patent/PL358675A1/xx unknown
- 2001-07-21 PT PT01958002T patent/PT1305041E/pt unknown
- 2001-07-21 WO PCT/EP2001/008455 patent/WO2002009745A1/de active IP Right Grant
- 2001-07-21 CZ CZ20030179A patent/CZ299669B6/cs not_active IP Right Cessation
- 2001-07-21 CA CA002417374A patent/CA2417374A1/en not_active Abandoned
- 2001-07-21 AU AU2001279775A patent/AU2001279775A1/en not_active Abandoned
- 2001-07-21 US US09/926,630 patent/US20030129206A1/en not_active Abandoned
-
2003
- 2003-01-21 BG BG107482A patent/BG107482A/bg active Pending
- 2003-01-27 NO NO20030420A patent/NO20030420L/no not_active Application Discontinuation
- 2003-10-27 HK HK03107742A patent/HK1055562A1/xx not_active IP Right Cessation
-
2006
- 2006-08-29 CY CY20061101216T patent/CY1105179T1/el unknown
- 2006-11-06 US US11/593,132 patent/US20070134275A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20030420D0 (no) | 2003-01-27 |
| HK1055562A1 (en) | 2004-01-16 |
| ES2267800T3 (es) | 2007-03-16 |
| WO2002009745A1 (de) | 2002-02-07 |
| US20070134275A1 (en) | 2007-06-14 |
| CZ299669B6 (cs) | 2008-10-08 |
| SK822003A3 (en) | 2004-05-04 |
| JP2004505058A (ja) | 2004-02-19 |
| NO20030420L (no) | 2003-01-27 |
| DK1305041T3 (da) | 2006-10-23 |
| ATE330626T1 (de) | 2006-07-15 |
| HUP0300772A3 (en) | 2005-11-28 |
| CA2417374A1 (en) | 2003-01-27 |
| EP1305041A1 (de) | 2003-05-02 |
| US20030129206A1 (en) | 2003-07-10 |
| BG107482A (bg) | 2003-11-28 |
| PL358675A1 (en) | 2004-08-09 |
| DE50110274D1 (de) | 2006-08-03 |
| CY1105179T1 (el) | 2010-03-03 |
| EP1305041B1 (de) | 2006-06-21 |
| HUP0300772A2 (en) | 2003-08-28 |
| SI1305041T1 (sl) | 2006-12-31 |
| AU2001279775A1 (en) | 2002-02-13 |
| CZ2003179A3 (cs) | 2004-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU23202A (sh) | Lekovi za tretman malignih tumora | |
| SE0002320D0 (sv) | Malignant tumors | |
| BRPI0207961A8 (pt) | Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
| SE9901875D0 (sv) | Novel compounds | |
| BRPI0409133A (pt) | formulações farmacêuticas contendo metilnaltrexona | |
| TR200103018T2 (tr) | İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri. | |
| CL2008000020A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos. | |
| BRPI0608297A2 (pt) | composições de lipossomos | |
| AU2001233726A1 (en) | Farnesyl protein transferase inhibitors for treating breast cancer | |
| MY128924A (en) | Novel compounds | |
| CY1105179T1 (el) | Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων | |
| BR0015597A (pt) | Uso de anticorpos como vacinas | |
| DE60123117D1 (de) | Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs | |
| TW200504051A (en) | Novel acridine derivatives and their use as medicaments | |
| BR0008305A (pt) | Utilização de uma proteìna ompa de enterobactéria, ou de um de seus fragmentos e composição farmacêutica | |
| BRPI0515533A (pt) | forma de dosagem estável de derivados de fenilalanina | |
| UA87292C2 (ru) | Применение сирамезина для лечения злокачественных опухолей | |
| DE60235085D1 (de) | Herstellungsverfahren von derivate von bisphosphonaten | |
| BR0301547C1 (pt) | composição farmacêutica para tratar patologia fúngica compreendendo lectina km+, composição farmacêutica para prevenir patologia fúngica compreendendo lectina km+, uso de lectina km+ para preparar medicamento para tratar patologia fúngica, uso de lectina km+ para preparar medicamento para prevenir patologia fúngica | |
| EA200600987A1 (ru) | Применение сирамезина в лечении злокачественных опухолей | |
| ECSP003491A (es) | Nuevas indolinonas sustituidas, su preparacion y su empleo como medicamentos | |
| UY26180A1 (es) | Nuevas indolinonas sustituidas, su preparación y su empleo como medicamentos | |
| ECSP034662A (es) | Compuestos de pirazol utiles como inhibidores de protein quinasa |